Introduction {#s02}
============

Each day humans require the production of about 100 billion blood cells. Rare hematopoietic stem cells (HSCs) are required to replenish multilineage progenitors, which can then differentiate into lineage-restricted cells (reviewed by [@bib83]). These unique HSCs reside in specialized niches and rely on critical niche factors to regulate their maintenance, self-renewal, differentiation, and regeneration after injury. There is currently a large effort to generate and engineer HSCs in vitro for research and therapy (reviewed by [@bib87]). HSC transplantation (HSCT) is a curative therapy to treat a wide variety of hematological malignancies, but numbers of immunologically matched HSCs are a limiting factor in such treatments ([@bib38]). More research is needed to understand cell-autonomous and non-cell-autonomous regulation of HSC induction, homing, and engraftment. If we can further our understanding of developmental hematopoiesis and identify key regulators of these processes in vivo, it may be possible to apply this knowledge to in vitro efforts to derive patient-specific HSCs from induced pluripotent stem cells (iPSCs). This would help overcome current issues of limiting cell number and graft-versus-host disease. Zebrafish are an ideal model to use to study hematopoiesis. The sites of blood development and the molecular signals regulating hematopoiesis are conserved with mammalian systems, and zebrafish embryos are transparent, allowing for noninvasive visualization of HSC emergence, migration, and engraftment. Zebrafish are also amenable to forward genetic and chemical screening, making them a useful tool to uncover novel regulators of blood development.

Overview of zebrafish hematopoiesis and techniques {#s03}
==================================================

The zebrafish has emerged as a powerful model for the study of hematopoiesis. There are many strengths that make this system ideally suited to the study of both hematopoietic development and disorders. Zebrafish embryos are fertilized externally, develop rapidly, and are amenable to genetic modification, which allows relatively straightforward creation of transgenic reporter lines labeling specific cell populations. In addition, the transparency of the embryos has enabled real-time visualization of the emergence, migration, and behavior of blood cells as they populate the embryo and adult, both during endogenous development and upon various chemical or genetic perturbations. These unique attributes have uncovered novel genes, cell types, and cellular behaviors that are required for normal vertebrate hematopoiesis.

Developmental hematopoiesis is conserved across species {#s04}
-------------------------------------------------------

Vertebrate hematopoiesis occurs during two waves of development. Hematopoietic cells that support early stages of development are formed during the primitive wave (reviewed by [@bib83]). Primitive erythroid cells, important for oxygenation of rapidly growing tissues, are formed in the intermediate cell mass (ICM), which is derived from the posterior lateral mesoderm (PLM; reviewed by [@bib83]). Primitive macrophages are formed in the anterior lateral mesoderm and initiate innate immunity ([@bib97]). Before the onset of definitive hematopoiesis, a transient population of multipotent erythromyeloid progenitors emerges from the ICM and seeds the fetal liver in mammals, or the caudal hematopoietic tissue (CHT) in zebrafish (reviewed by [@bib17]). The hallmark of definitive hematopoiesis is the induction of HSCs, which can self-renew and give rise to more committed progenitors, such as myeloid and lymphoid cells (reviewed by [@bib83]). Definitive HSCs bud off from specialized endothelial cells of the aorta-gonad mesonephros (AGM) region, known as hemogenic endothelium, and migrate to successive niche sites as hematopoiesis occurs sequentially ([@bib88]; [@bib4]; [@bib8]; [@bib53]). In mammals, definitive HSCs migrate to and colonize the placenta, fetal liver, thymus, spleen, and finally the bone marrow, which is the adult hematopoietic niche (reviewed by [@bib83]). In zebrafish, HSCs are born in the AGM around 30 h post fertilization (hpf; [@bib4]; [@bib53]) and migrate to the CHT, a vascular plexus in the tail, starting around 36 hpf ([@bib74]; [@bib94]). HSCs begin to populate the thymus and kidney, the adult stem cell niches in zebrafish, at 4 d post fertilization (dpf; [@bib74]; [@bib83]).

Understanding the origin of HSCs {#s05}
--------------------------------

Investigation into the origin of HSCs indicated that human endothelial cells isolated from the embryonic dorsal aorta have the potential to differentiate into myeloid and lymphoid progeny when cultured in vitro ([@bib81]). Lineage tracing experiments in mouse and chick models also suggested that the intra-aortic clusters that give rise to HSCs are derived from endothelial cells ([@bib47]; [@bib106]). However, there remained some debate over whether the HSCs were born in the aortic floor itself or in the subaortic mesenchyme ([@bib3]; reviewed by [@bib26]). The unique strengths of the zebrafish enabled the first real-time, in vivo visualization of the emergence of HSCs in their native environment, and live imaging of developing zebrafish embryos confirmed their endothelial origin ([@bib4]; [@bib53]). Transgenic reporter lines with fluorescently labeled hematopoietic stem and progenitor cells (HSPCs), such as *cmyb:eGFP* and *cd41:GFP*, combined with the endothelial marker *kdrl:mCherry* or *lmo2:dsred*, have enabled the direct observation of HSPCs as they first arise from specialized hemogenic endothelium in the AGM. Between 28 and 32 hpf, endothelial cells lining the ventral wall of the dorsal aorta begin to contract and change shape, becoming more spherical and forming buds that extend into the aortic lumen ([@bib4]; [@bib53]). At the same time, they begin to express the HSPC-specific genes *cmyb* and *cd41*. During this process, which has been termed the endothelial hematopoietic transition (EHT; [@bib53]), nascent HSPCs bud off into the subaortic space before entering circulation via the dorsal wall of the cardinal vein, to migrate to the intermediate stem cell niche in the CHT ([@bib54]).

Using genetic and chemical manipulation to understand hematopoietic development {#s06}
-------------------------------------------------------------------------------

Zebrafish are extremely amenable to genetic manipulations, including overexpression by microinjection of RNA or DNA; knockdown by morpholino, TALENs, or CRISPR; or unbiased approaches such as large-scale forward genetic screens (reviewed by [@bib2]). Since the breakthrough genetic screens of the 1990s, forward genetics in zebrafish has been used to identify important and novel genes in hematopoietic development, many of which have roles in known human diseases ([@bib32]; [@bib43]; [@bib85]; reviewed by [@bib23]). For example, the ferroportin 1 iron transporter was first isolated from a zebrafish mutant, and then similar mutations were found in human patients with iron-overload disorders ([@bib29]; [@bib37]). Insertional mutagenesis screens have also been used to probe hematopoiesis and have identified mutations associated with human diseases, such as Diamond-Blackfan anemia ([@bib95]; [@bib70]).

Chemical screening in zebrafish has uncovered essential hematopoietic signaling that is conserved in mammals and is a powerful model for drug discovery. Zebrafish are an ideal model for screening both new small molecules and libraries of US Food and Drug Administration--approved drugs to examine how they modulate a specific phenotype of interest or disease model (reviewed by [@bib2]). Thousands of zebrafish embryos can easily be obtained and screened as intact embryos with temporal control. One of the best examples of chemical screening success is that of prostaglandin E~2~ (PGE~2~), which increases the number of HSPCs in the zebrafish AGM ([@bib79]). A 2-h pulse treatment of PGE~2~ is also sufficient to increase the long-term repopulation activity of mouse HSPCs, demonstrating conservation. Currently, a human clinical trial is under way to determine whether PGE~2~ treatment of umbilical cord blood enhances HSCT. In the phase I trial, PGE~2~-treated cells preferentially engrafted in 10 of 12 patients ([@bib19]). Competitive HSPC transplantation can also be done in adult zebrafish. Such transplantation was combined with a chemical screen to determine that 11,12-epoxyeicosatrienoic acid enhances HSPC specification, homing, and engraftment ([@bib64]). Other emerging techniques in zebrafish include surgical parabiosis, in which embryos of two different genotypes or treatment can be conjoined with a shared circulation to examine the autonomous or nonautonomous role of various genes or factors in controlling HSPC migration and engraftment ([@bib24]; [@bib44]).

Work in both mammals and zebrafish has shed light on the critical processes that regulate blood development and disease, but further efforts are needed to improve HSC transplant therapies. Recent studies in zebrafish, including time-lapse imaging and forward genetic screens, have revealed novel cell--cell interactions and signaling pathways that regulate HSPC induction, migration, and homing, and it may be possible to apply these new findings to strategies to develop HSCs in vitro for therapeutic purposes.

Transcriptional regulation of HSC specification {#s07}
===============================================

The specification and emergence of HSCs in the AGM are regulated by a plethora of molecular and biochemical signaling pathways, which are highly conserved between zebrafish and mammals. Many of these signaling pathways rely on the controlled and coordinated expression of transcription factors, which are fundamental drivers of cell fate. Recent studies have used transcription factor reprogramming approaches to try to generate HSCs in vitro, but these are not yet equivalent to bona fide HSCs (reviewed by [@bib87]). Furthering our understanding of the precise transcription factors that are required to regulate the emergence of definitive HSCs may reveal new molecular pathways that could be targeted to improve these HSC engineering strategies. Recent zebrafish studies have revealed new insights into the regulation of HSC induction by Notch1 and other transcription factors.

Regulation of HSC induction by Runx1 signaling {#s08}
----------------------------------------------

Runx1 is the master regulator of definitive HSC specification across species ([@bib78]; [@bib15]; [@bib4]; [@bib53]). Early studies in mice revealed that this key hematopoietic transcription factor is essential for definitive hematopoiesis ([@bib82]), as mice lacking *Runx1* fail to initiate fetal liver hematopoiesis and are embryonic lethal. In zebrafish embryos lacking *runx1*, EHT events are aborted, and any cells that do emerge rapidly burst into pieces ([@bib53]). *Runx1* expression is regulated by the transcription factors Gata2, Scl, and Lmo2 ([@bib80]), which are required for both primitive and definitive hematopoiesis ([@bib98]; [@bib90]; [@bib102]). As in mammalian systems, Scl and Lmo2 are also fundamentally required for zebrafish hematopoiesis, and deletion of either factor results in loss of both primitive and definitive blood lineages ([@bib30]; [@bib84]). There are two isoforms of *scl* in zebrafish, which have distinct temporal requirements. The *sclb* isoform is expressed first in hemogenic endothelial cells before EHT, and the *scla* isoform is expressed later during HSC budding ([Fig. 1 A](#fig1){ref-type="fig"}; [@bib105]). Expression of *sclb* is dependent on adenosine signaling, which regulates hemogenic endothelium formation and enhances HSPC development ([@bib50]). Zebrafish also express two *Gata2* homologues, *gata2a* and *gata2b*, the latter of which is specifically expressed in hemogenic endothelial cells and is essential for HSC emergence ([@bib12]).

![**HSC specification is regulated by transcriptional signaling throughout development.** (A) Zebrafish studies have revealed transcription factors that are important at different stages of definitive hematopoiesis: hemogenic endothelial formation, HSC specification in the AGM, and HSC budding. (B) Recent studies in zebrafish have identified Notch signaling pathways in the somite that influence HSC specification. Wnt16 signaling induces expression of Notch ligands DeltaC and DeltaD, which interact with Notch1 receptors on vascular precursors from the posterior lateral mesoderm (PLM) as they migrate over the somite surface. This interaction is dependent on the junctional adhesion molecules Jam1a and Jam2a. Notch3 is also expressed in the somite and may provide additional inductive cues to HSCs via the sclerotome. Endothelial precursor cells derived from the endotome are specified by the homeobox gene *meox1* and migrate to the dorsal aorta, where they contribute to *cxcl12*-dependent HSC induction. nc, notochord; nt, neural tube.](JEM_20171069_Fig1){#fig1}

Regulation of HSC induction by Notch signaling {#s09}
----------------------------------------------

Notch1 is a key transcriptional regulator required for the development of repopulating HSCs from hemogenic endothelium ([@bib57]; [@bib41]) and has been used in efforts to expand HSCs from endothelium in vitro with some success ([@bib42]). Notch1 is a conserved regulator of HSC emergence and acts in multiple cell-autonomous and non-cell-autonomous ways to regulate HSC emergence, but we still do not fully understand these mechanisms (reviewed by [@bib13]). Canonical Notch signaling occurs when the extracellular Notch transmembrane receptor is activated by a transmembrane ligand on a neighboring cell ([@bib76]). This induces cleavage and release of the Notch intracellular domain, which translocates to the nucleus, where it functions as a transcription factor. Signaling pathways involving Bmp ([@bib100]), Wnt ([@bib36]; [@bib18]), Shh ([@bib60]; [@bib35]; [@bib100]), and Vegfa ([@bib35]; [@bib11]) are required for development of the arterial endothelium, activation of the Notch pathway, and specification of definitive HSCs. Notch signaling is required for successful EHT and HSC emergence and activates the expression of many hematopoietic genes, including *scl*, *gata2*, and *runx1* ([@bib10]; [@bib76]). The Notch intracellular domain activates *Hes1*, *Hes5*, *Foxc2*, and *Gata 2* ([@bib86]; [@bib40]; [@bib48]), and Notch signaling indirectly regulates Runx1 via this activation of Gata2 ([@bib57]; [@bib41]; [@bib86]), which interacts with Fli-1 and the Scl/Lmo2/Ldb1 complex to form a transcriptional signaling center that drives *Runx1* expression ([@bib80]). Studies show that the loss of Notch signaling pathway components results in reduced numbers of functional HSCs. For instance, the zebrafish *mind bomb* mutant, in which an E3 ligase required for Notch ligand ubiquitination and internalization is mutated, fails to specify definitive HSCs ([@bib10]; [@bib5]). Primitive hematopoiesis remains unaffected, and the same phenotype is observed with this mutation in mammalian systems ([@bib103]). The Notch1 receptor is essential for specification of definitive HSCs in a cell-autonomous manner, and its deletion in mice and zebrafish results in reduced HSC emergence from the hemogenic endothelium ([@bib57]; [@bib41]; [@bib51]). In contrast, the Notch2 receptor is dispensable ([@bib57]; [@bib51]). Recently, Notch-mediated EHT has been shown to be dependent on the transcriptional regulator Evi1, which activates Notch via pAKT ([@bib56]).

Zebrafish studies have also revealed a novel requirement for Notch signaling in HSC development that occurs in a non-cell-autonomous manner ([@bib18]). Fgf signaling in the somite from 14 to 17 hpf, before the onset of definitive hematopoiesis, activates Wnt16, which induces somitic expression of the Notch ligands DeltaC and DeltaD ([Fig. 1 B](#fig1){ref-type="fig"}; [@bib18]; [@bib62]). These ligands are required to induce hematopoietic potential in vascular precursors from the PLM as they migrate over the ventral surface of the somite. The transduction of Notch signals between the somite and precursor cells is dependent on close association of the two cell types, which is achieved via interaction of the junctional adhesion molecules *jam1a* (expressed on the PLM cells) and *jam2a* (expressed on the somite cells; [@bib55]). Knockdown of either of these molecules in zebrafish embryos results in a loss of Notch signaling and reduced HSC numbers. Non-cell-autonomous regulation of HSC specification is also mediated by *notch3*, which is expressed in the somites at 14 hpf ([@bib51]). This receptor is activated by DeltaC and DeltaD, downstream of Wnt16. It is not yet clear how this somite-intrinsic signaling affects HSC specification, but it has been shown that both Notch3 and Wnt16 are essential for specification of the sclerotome, which is believed to provide additional inductive cues to HSCs ([@bib51]). Recently, it was found that *wnt16* expression is potentiated by the regulatory factor Rspo1, which also up-regulates *vegfaa* in the somite ([@bib34]). This activates TGFβ signaling in the hemogenic endothelium, which is required for HSC specification via up-regulation of the Notch ligand *jag1a* ([@bib71]). Further studies are required to establish the precise interactions between signaling pathways in the somite and hemogenic endothelial cells over the course of their development, which would help determine the transcription factors that are required for HSC specification in a non-cell-autonomous manner. These, along with other signaling factors from the stem cell niche, are likely to be essential for the successful generation of HSCs in vitro for therapeutic purposes.

Regulation of HSC induction by HOX genes {#s10}
----------------------------------------

Several homeodomain-containing transcription factors, including HOXA9, HOXB3, and HOXB4, are highly expressed in HSPCs, but the mechanisms by which they regulate hematopoiesis are not fully understood (reviewed by [@bib1]). Knockdown of *Hoxa9*, *Hoxb3*, and *Hoxb4* in mice leads to a reduction in the repopulating capacity of HSCs and a deficiency in myeloid and lymphoid precursors ([@bib67]). An important role for *hox* genes has also been demonstrated in zebrafish HSC development. Mutations in the upstream activator of *hox* genes, *cdx4*, cause hematopoietic defects and aberrant *hox* gene expression ([@bib22]). These defects can be rescued by overexpression of *hoxb7a* or *hoxa9a*. The additional knockdown of *cdx1* in the *cdx4* mutant background results in a complete loss of blood cell specification, and overexpression of *hoxa9* in this situation rescues both embryonic erythropoiesis and HSC formation in the AGM ([@bib21]). Overexpression of *cdx4* leads to ectopic blood development, both in wildtype zebrafish embryos and mouse embryonic stem cells (ESCs; [@bib20]; [@bib63]). These studies highlight the importance of *hox* genes as master regulators of HSC development, which supply key spatial and temporal information and may provide an important missing link to generate human HSCs from iPSCs. Early efforts to derive HSCs from mouse ESCs used overexpression of *Hoxb4* to generate hematopoietic cells with some engraftment capacity ([@bib58]), and more recent transcriptional reprogramming strategies have used HOX genes in combination with other transcription factors ([@bib31]; [@bib93]). In the most recent study, HOXA5, HOXA9, and HOXA10 were used alongside ERG, LCOR, RUNX1, and SPI1 to convert hemogenic endothelium to HSPCs with multilineage engraftment potential ([@bib93]). Further studies are necessary to precisely define the function of homeotic genes in HSC development.

Transcriptional regulation of budding HSCs {#s11}
------------------------------------------

In addition to advancing our understanding of hemogenic endothelium development and HSC fate specification, zebrafish studies have also revealed insight into several additional transcriptional regulators that are critical for the release of nascent HSCs from the hemogenic endothelium. In zebrafish embryos with deletion of the Runx1-binding cofactor *cbfb*, HSCs are unable to extravasate from the dorsal aorta and definitive hematopoiesis does not occur ([@bib9]). Deletion of Cbfb in mice blocks fetal liver hematopoiesis and causes embryonic lethality ([@bib99]). HSC release is also inhibited in zebrafish with mutations in the *cmyb* gene, which encodes another transcription factor required for HSC maintenance ([@bib104]). Cmyb function is conserved in mammalian systems; in *Cmyb* mutant mice, impaired mobilization of HSCs from the AGM is indicated by reduced fetal liver hematopoiesis ([@bib73]). Further research is necessary to broaden our understanding of the mechanisms that allow release of HSCs from the endothelium, which will be important for establishing efficient ways to generate large numbers of HSCs in vitro.

Understanding HSC--niche interactions {#s12}
=====================================

HSPCs intimately interact with niche cells throughout their development from specification to migration to engraftment (reviewed by [@bib72]). HSC development relies on intimate interactions with niche cells of the microenvironment, which provide important signaling factors and physical properties. The ability to successfully engineer HSCs will likely rely on the incorporation of niche-derived factors and cues, and reprogramming studies have illustrated the importance of the vascular niche for the emergence of definitive hematopoietic cells ([@bib61]; [@bib16]; [@bib92]; [@bib33]; [@bib65]). There is currently much that is not understood about niche ontogeny, gene expression, and function. Recent studies in zebrafish have elucidated new roles for niche cells in regulating HSC induction, migration, maintenance, and differentiation.

Niche interactions and signaling in the mammalian bone marrow niche {#s13}
-------------------------------------------------------------------

After HSCs bud off from the hemogenic endothelium, they enter circulation and home to successive sites of hematopoiesis (reviewed by [@bib83]). Homing to the niche and lodgment within that niche are critical processes that must occur both in development and in transplant ([@bib45]). The cellular and chemical composition of the adult mammalian bone marrow niche is made up of multiple types of stromal cells, endothelial cells, osteoblasts and osteoclasts, sympathetic nerves, megakaryocytes, and macrophages, among others, and is the subject of a large body of work (reviewed by [@bib69]; [@bib72]; [@bib6]). For the past decade researchers have been working to elucidate the cell types and signals in the bone marrow niche that are essential for HSC homeostasis. Stromal cells and endothelial cells of the vascular niche are important sources of the two main niche factors, chemokine CXCL12 (also known as stromal derived factor-1) and cytokine KIT ligand (KITLG; also known as stem cell factor; [Fig. 2 A](#fig2){ref-type="fig"}). CXCL12 and KITLG promote HSC localization to, and maintenance within, the perivascular niche (reviewed by [@bib52]; [@bib28]; [@bib27]; [@bib39]; [@bib72]). These factors are expressed at much higher levels by stromal cells but are required in both cell types for niche function. Both endothelial and stromal cells maintain HSCs through KITLG and CXCL12 signaling, and efforts are under way to mimic this niche in vitro*.* Hematopoietic progenitors can be obtained when ESC- or AGM-derived cells are cultured with stromal cells, but the efficiency of this process needs to be improved ([@bib61]; [@bib16]; [@bib92]). In an alternative approach, nonhematopoietic endothelial cells can be reprogrammed into engraftable hematopoietic cells but only if they are in contact with a vascular niche, indicating a requirement for inductive and supportive signals from associated endothelial cells ([@bib89]).

![**Stromal and endothelial cells in the vascular niche modulate Cxcl12 and Kitlg signaling to regulate HSCs.** (A) The mammalian bone marrow contains multiple types of perivascular stromal cells and endothelial cells in the vascular niche. Stromal and endothelial cells are both required to express niche factors Cxcl12 and Kitlg to influence HSC localization, maintenance, retention, and quiescence. Stromal cells express these factors at ∼1,000× greater levels. (B) HSPCs colonize the caudal hematopoietic tissue in the 48 hpf zebrafish. Within the niche, multiple factors influence the expression of niche factors Cxcl12 and Kitlg in the CHT. Vascular endothelial cells require expression of transcription factor *tfec* and chemokine receptor *cxcr1* to regulate expression of *kitlgb* and *cxcl12a*, respectively, to control HSPC engraftment and expansion. *mmp9* expressed by neutrophils in the niche cleaves *cxcl12* to promote HSPC egress and colonization of secondary niches.](JEM_20171069_Fig2){#fig2}

Novel niche interactions and signaling required for HSC homeostasis in zebrafish {#s14}
--------------------------------------------------------------------------------

HSPCs also interact with multiple cell types in the zebrafish niche, including endothelial cells, stromal cells, macrophages, and neutrophils, among others ([@bib94]). Purified cell lines from the AGM, CHT, and kidney stroma have been shown to support hematopoiesis ([@bib91]; [@bib14]; [@bib101]). Recent work in zebrafish has revealed novel cell--cell interactions that are important for HSPC migration and engraftment. The transparency of the zebrafish embryo makes it ideally suited for live imaging of intimate HSC-niche interactions. Although recent studies in the mouse have optimized imaging in the endosteal niche in the calvarium of the skull ([@bib66]; [@bib59]), zebrafish offers unparalleled opportunities for long-term and continuous noninvasive imaging of endogenous processes. Live imaging was used to track HSCs from their birthplace in the AGM to the fetal CHT niche and to the adult thymus and kidney niches ([@bib74]; [@bib54]). Recently our laboratory developed a novel transgenic zebrafish line to more specifically label HSPCs ([@bib94]). [@bib94] cloned a mouse regulatory region located in the first intron of the transcription factor Runx1 upstream of GFP to mark definitive HSPCs in zebrafish. This transgenic line allowed for high-resolution mapping of the dynamic cell--cell interactions that occur during HSPC homing and niche engraftment in unperturbed embryos. Multiple HSPC-endothelial cell interactions were observed during HSPC engraftment. As described in mammals, HSPCs migrate through circulation to the niche, adhere to the endothelium, and extravasate across the endothelial cell wall. High-resolution imaging revealed a novel behavior where the arrival of the HSPC triggers a remodeling of the endothelial cells to surround the HSPC in a niche pocket, termed "endothelial cell cuddling" ([Fig. 2 B](#fig2){ref-type="fig"}; [@bib94]). Within the pocket, HSPCs are anchored to mesenchymal stromal cells, which orient the division axis of the stem cell. Imaging in dissected mouse fetal livers showed that endothelial cells similarly surround HSPCs in the mammalian fetal niche, indicating it is a conserved cell--cell interaction ([@bib94]). Future studies will reveal the functional effect of these endothelial and stromal cell interactions on the fate of the HSC.

Two recent studies identified novel somite-derived cell types that are required in the AGM for HSC induction, and in the CHT for HSPC retention. [@bib77] found that a subset of somite-derived cells, known as endotome, form endothelial cells in the dorsal aorta of the AGM, express niche factor *cxcl12b*, and induce HSC formation. Homeobox gene *meox1* was found to be expressed in a subset of somitic muscle cells and is required to specify somitic cell fates. In *choker* mutants, which have a null mutation in *meox1*, endotome cells are expanded, increasing Cxcl12b signaling and thus HSC induction ([@bib77]). The authors suggested that to be able to generate HSCs in vitro*,* somite-derived endothelial cells might be required to serve as niche cells and promote induction. [@bib75] identified a distinct population of somite-derived stromal niche cells that are required in the fetal CHT niche for HSPC maintenance, expansion, and differentiation. The gene nascent polypeptide-associated complex, which is mutated in *oloca* mutants, is required cell autonomously for stromal cell maturation and survival in the developing CHT ([@bib75]). HSPCs can home to the CHT in the absence of these stromal cells, but *naca* is required nonautonomously in stromal cells for HSPC retention in the niche and subsequent expansion and differentiation of the stem cells ([Fig. 2 B](#fig2){ref-type="fig"}). In the absence of *naca*, these somite-derived stromal cells apoptose because of activation of the unfolded protein response ([@bib75]). These studies revealed a new role for somite-derived cells in HSC specification in the AGM, and in HSC expansion and differentiation in the fetal niche. These novel genes and cell types critical in HSC development were both identified through zebrafish forward genetic screens. Further studies will determine whether these cells and signals are important in mammalian HSC development.

Additional studies have uncovered new ways that niche signals Kitlg and Cxcl12 are modulated to regulate HSC retention, expansion, and egress from the niche ([Fig. 2 B](#fig2){ref-type="fig"}). The transcription factor Tfec was recently found to enhance HSC expansion in mouse HSCs nonautonomously through unknown mechanisms ([@bib25]). Studies in zebrafish determined that *tfec* is expressed in caudal endothelial cells, the region where the CHT niche will form, and is required for HSPC maintenance ([@bib68]). Mahoney et al. (2016) found that *tfec* acts nonautonomously in the vascular niche to regulate HSC expansion by controlling expression of cytokines, including *kitlgb*. Overexpressing *kitlgb* is sufficient to rescue HSPC expansion in mutants lacking *tfec.* Endothelial cell-derived niche signals are critical for proper HSPC development. In complementary experiments, gene expression profiling identified that niche-derived *cxcl8*/*cxcr1* signaling enhances HSPC niche colonization by remodeling the vascular CHT niche ([@bib7]). Chemokine *cxcl8* and its receptor *cxcr1* are expressed in endothelial cells in the CHT, and this signaling positively regulates the amount of time HSPCs spend in the niche and the number of divisions and cuddling events that take place there. Increasing *cxcr1* expression induces *cxcl12a* expression and increases the volume of the vascular niche. Through these mechanisms, *cxcr1* acts nonautonomously to increase HSPC niche engraftment ([@bib7]). CXCL12 regulation of HSC migration is also regulated by matrix metalloproteinase 9 (MMP9) signaling in the adult bone marrow ([@bib49]). MMP9 can degrade CXCL12 in plasma from human mobilized bone marrow to promote migration of CD34^+^ HSCs ([@bib49]). In the zebrafish fetal niche, *mmp9* expressed by neutrophils was recently shown to regulate HSPC homeostasis through regulation of *cxcl12* expression ([@bib96]). Mmp9 activity was shown to be required for HSPC egress from the CHT and is required for colonization of secondary niches. Absence of *mmp9* signaling led to vascular changes in the niche and retention of HSPCs in the CHT. These migration defects were blocked by knocking down *cxcl12a* signaling or phenocopied by overexpressing *cxcl12b*, indicating that Mmp9 is required to modulate this signaling axis to regulate HSPC homeostasis ([@bib96]). Together these studies have demonstrated that vascular-derived *tfec* and *cxcr1* signaling, and neutrophil-derived *mmp9* are important for regulating the vascular HSC niche, while expression of *kitlgb* and *cxcl12* is important for controlling HSPC maintenance and migration. Modulation of these cell--cell interactions or signaling molecules could be of potential therapeutic benefit to patients receiving HSCT.

Concluding thoughts {#s15}
===================

Recent studies in zebrafish have capitalized on the unique experimental strengths of the system to probe the mechanisms of HSPC specification and niche interactions during HSPC emergence, migration, and engraftment. Continued efforts using emerging technologies in the zebrafish will reveal new insights into important aspects of hematopoiesis. Single-cell RNA sequencing will allow researchers to identify cell-specific gene expression, which can be used to more precisely mark distinct hematopoietic populations. Cell type--specific promoters will allow more detailed time-lapse imaging, lineage tracing, and gene knockout experiments, when combined with CRISPR/Cas9 technology. Multicolor fate mapping methods, such as Zebrabow, can be used to track HSC clonal dynamics in steady-state and in disease ([@bib46]). The unique strengths of the zebrafish have illuminated critical signaling pathways and cell--cell interactions that are conserved in mammalian hematopoiesis. New insights into the transcriptional regulation of HSC induction by factors such as Notch1, Runx1, and Cbfβ have highlighted the complexity of these signaling networks and the dynamic interactions that occur between HSC precursors and other cell types (reviewed by [@bib9]; [@bib13]). Zebrafish studies have also uncovered novel cell--cell interactions, such as endothelial cell cuddling ([@bib94]), novel cell types, such as somite-derived niche cells ([@bib77]; [@bib75]), and novel regulators of niche signals, such as Tfec and Cxcr1 ([@bib68]; [@bib7]). It may be important to recapitulate these processes and signals to generate definitive HSCs that can be used in the clinic. The ability to bioengineer patient-compatible HSCs would greatly enhance lifesaving bone marrow transplantation therapies used to treat patients with a variety of leukemias, lymphomas, anemias, and immunodeficiencies. Autologous transplantation of patient-derived HSCs would reduce the risks associated with allogeneic cell transplantation, such as immune rejection and graft-versus-host disease. Continued efforts to further characterize both the autonomous transcription factors that specify HSCs and the nonautonomous cell types and signals that are essential for HSC homeostasis are required to robustly engineer HSCs for therapeutic use.
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